Replies to post #163994 on Biotech Values

[iwfal]

XOMA

I found treatment arm response rates in NIU trials that I've looked at, mostly TNF-alpha inhibitors, are generally 50% or better. However the response endpoint often consisted of a basket of metrics, e.g. visual acuity, different inflammation scores, tapering of current drugs, and meeting only one criteria qualified as a responder.

My conclusion as well - and to state the obvious, indicating that VH piece was lower than 50% and thus potentially much less potent than Gev appears to be. But obviously with all the risk that always comes with comparing across trials.

What I have been trying to get my arms around is determining how well the various individual response rate metrics across trials correlate to an improvement in VH score

That would be a step beyond what I've done - so would be of especial interest.